Related by context. All words. (Click for frequent words.) 78 relapsed MM 77 CYT# potent vascular disrupting 76 unresectable tumors 76 relapsing remitting MS RRMS 76 metastatic malignant 76 CIMZIA TM certolizumab pegol 76 MGd 76 metastatic GIST 75 AA Amyloidosis 75 MAGE A3 ASCI 75 papillary renal cell carcinoma 75 leukemia AML 75 Adjuvant chemotherapy 75 paclitaxel cisplatin 75 myelodysplastic myeloproliferative diseases 75 abacavir Ziagen 74 Doxil ® 74 dasatinib Sprycel ® 74 Aflibercept 74 non splenectomized 74 stage IIIb IV 74 NMIBC 74 antiretroviral naïve 74 superficial bladder cancer 74 trastuzumab Herceptin ® 74 gastrointestinal stromal tumor GIST 74 mRCC 74 antibody MAb 74 hepatorenal syndrome 74 metastatic gastric 73 Myelodysplastic Syndrome MDS 73 forodesine 73 metastatic bladder 73 demonstrated antitumor activity 73 ACTEMRA TM 73 erlotinib Tarceva ® 73 FUSILEV enhances 73 KRAS mutations occur 73 colorectal liver metastases 73 riociguat 73 gastrointestinal stromal tumors GIST 73 eosinophilic asthma 73 hypereosinophilic syndrome 73 differentiated thyroid 73 recurrent NSCLC 73 Glioblastoma Multiforme 73 chemoradiation therapy 73 recurrent glioblastoma 73 nonmetastatic 73 PREZISTA r 73 ritonavir boosted 73 estramustine 73 tumors GIST 73 unstable angina UA 73 adriamycin 73 mitoxantrone plus 73 vinca alkaloid 73 essential thrombocythemia ET 73 recurrent glioblastoma multiforme GBM 73 Glioblastoma Multiforme GBM 73 alkylating agent 73 biliary tract cancer 73 metastatic malignant melanoma 73 thalidomide Thalomid 73 Surgical resection 73 evaluating tivozanib 73 sorafenib Nexavar 73 complement inhibitor eculizumab 73 cilengitide 73 Temsirolimus 73 ELACYT 73 HCV SPRINT 73 stage IIIB 73 Gleevec resistant 72 Enzastaurin 72 kidney urologic 72 metastatic colorectal carcinoma 72 metastatic renal cell carcinoma 72 de novo kidney transplant 72 adalimumab Humira 72 recurrent metastatic 72 Velcade bortezomib 72 recurrent glioma 72 ribavirin RBV 72 allogeneic hematopoietic stem cell 72 chronic eosinophilic leukemia 72 completely resected 72 HCV RESPOND 2 72 metastatic colorectal 72 HBeAg positive patients 72 malignant ascites 72 minimally symptomatic 72 Ribavirin causes 72 thymoma 72 HBeAg negative 72 metastatic pancreatic 72 metastatic RCC 72 LHRH receptor positive 72 alfa 2a 72 Hepatocellular Carcinoma HCC 72 EXJADE 72 relapsing multiple sclerosis 72 opioid induced constipation OIC 72 Vidaza azacitidine 72 lenalidomide Revlimid R 72 colorectal cancer liver metastases 72 refractory chronic lymphocytic 72 TTF Therapy 72 anthracycline taxane 72 ZOLINZA 72 docetaxel Taxotere ® 72 heavily pretreated 72 receptor tyrosine kinase inhibitor 72 Heterozygous Familial Hypercholesterolemia 72 advanced metastatic renal 72 Mitoxantrone 72 Hodgkin lymphoma HL 72 rFVIIa 72 Gliadel Wafer 72 fosbretabulin 72 cetuximab Erbitux R 72 NATRECOR ® 72 HER2 positive metastatic breast 72 NATRECOR R 72 achieved CCyR 72 pegylated liposomal doxorubicin 72 humanised monoclonal antibody 72 GOUT 71 INCB# [003] 71 anthracyclines taxanes 71 recurrent malignant glioma 71 somatostatin analog 71 severe oral mucositis 71 Pharmacokinetics PK 71 Pemetrexed 71 Chronic lymphocytic leukemia 71 invasive candidiasis 71 relapsed refractory multiple myeloma 71 malignant pleural mesothelioma 71 chronic thromboembolic pulmonary 71 refractory acute myeloid 71 elevated transaminases 71 GW# [003] 71 cisplatin gemcitabine 71 Cloretazine 71 phase IIb study 71 squamous histology 71 keloid scarring 71 gefitinib Iressa 71 metastatic castration resistant 71 cisplatin chemotherapy 71 phase IIb clinical 71 paricalcitol 71 lenalidomide dexamethasone 71 fallopian tube cancers 71 CIMZIA TM 71 cutaneous T 71 refractory NSCLC 71 recurrent GBM 71 selective modulator 71 FluCAM arm 71 nucleoside analog 71 Mitomycin C 71 esophageal candidiasis 71 Sprycel dasatinib 71 YONDELIS 71 metastatic neuroendocrine tumors 71 prostate cancer CaP 71 glioblastoma multiforme GBM 71 relapsed multiple myeloma 71 Idiopathic Pulmonary Fibrosis 71 anterior uveitis 71 mycosis fungoides 71 Waldenstrom macroglobulinemia 71 cell lymphoma CTCL 71 Natalizumab 71 nucleotide analogue 71 alefacept 71 ZACTIMA 71 castrate resistant prostate cancer 71 BARACLUDE ® 71 placebo dexamethasone 71 sorafenib tablets 71 metastatic renal cell 71 psoriatic arthritis PsA 71 HBeAg negative patients 71 resectable pancreatic cancer 71 BRIM2 71 KRAS mutant tumors 71 Cutaneous T 71 PEGylated interferon beta 1a 71 underwent surgical resection 71 unresectable stage 71 alvespimycin 71 thetreatment 71 Peginterferon alfa 2b 71 gemcitabine Gemzar ® 71 CTEPH 71 #I TM# 71 standard chemotherapy regimen 71 dose escalation phase 71 invasive aspergillosis 71 underwent resection 71 treatment naive genotype 71 cediranib 71 randomized Phase IIb 71 FOLFOX6 71 HIV HCV coinfected 71 histologically confirmed 71 assessing T DM1 71 antiangiogenic therapy 71 CALGB # [002] 71 allogeneic HSCT 71 leukemia CLL 71 deep venous thromboses 71 relapsed leukemia 71 Nexavar sorafenib 71 Certolizumab pegol 70 Myelodysplastic Syndrome 70 receptor inhibitor 70 PEGylated Fab fragment 70 EGFR TKI 70 galiximab 70 erlotinib Tarceva 70 transplantation HCT 70 Lymphocytic 70 HER2 overexpression 70 relapsed CLL 70 hepatic metastases 70 OHR/AVR# 70 smoldering multiple myeloma 70 imatinib Gleevec ® 70 APTIVUS r 70 allogeneic stem cell 70 Decitabine 70 taxane chemotherapy 70 abacavir lamivudine 70 interferon ribavirin 70 prostate cancer CRPC 70 imatinib resistant 70 endometrial hyperplasia 70 neoadjuvant therapy 70 acute promyelocytic leukemia APL 70 morphometric vertebral fractures 70 5 fluorouracil leucovorin 70 colorectal carcinoma 70 pheochromocytoma 70 systemic anaplastic large 70 diabetic gastroparesis 70 epithelial ovarian 70 sunitinib Sutent ® 70 trastuzumab Herceptin R 70 Genasense ® 70 polycythemia vera essential thrombocythemia 70 metastatic hormone refractory 70 skeletal metastases 70 BEXXAR Therapeutic Regimen 70 Neovascular AMD 70 intravenous bisphosphonates 70 Flu Cy 70 Naive Patients 70 basiliximab 70 cancer mCRC 70 haematologic 70 cisplatin resistant 70 pancreatic adenocarcinoma 70 nab paclitaxel 70 SNT-MC#/idebenone 70 trial evaluating PRX# 70 nutlin 3a 70 familial amyloidotic polyneuropathy FAP 70 genotypic resistance 70 Bezielle 70 myelofibrosis polycythemia vera 70 MELAS 70 Cytoxan 70 EGFR expressing mCRC 70 immunomodulatory therapy 70 IV NSCLC 70 sunitinib malate 70 hyperphenylalaninemia HPA due 70 ovarian carcinoma 70 taxane resistant 70 severe neutropenia 70 antiretroviral naive 70 GRN# 70 recurrent genital herpes 70 coinfected patients 70 smoldering myeloma 70 candidemia 70 protease inhibitor PI 70 CLL SLL 70 oral prodrug 70 polycythemia vera PV 70 ß blockers 70 octreotide LAR 70 histologic subtype 70 radiolabeled TM# 70 pertuzumab 70 fallopian tube carcinoma 70 transarterial 70 huN# DM1 70 idiopathic thrombocytopenic purpura ITP 70 relapsed ovarian cancer 70 liver metastasis 70 ® lenalidomide 70 icatibant 70 omega interferon 70 ara C 70 comparator arm 70 non metastatic osteosarcoma 70 bevacizumab Avastin ® 70 Tarceva TM 70 gemcitabine carboplatin 70 SPRYCEL ® 70 desvenlafaxine succinate 70 Carotid Revascularization Endarterectomy vs. 70 K ras mutations 70 neratinib 70 IMiDs ® compound 70 calcineurin inhibitor 70 medically inoperable 70 ziconotide 70 tumor lysis syndrome 70 irinotecan chemotherapy 70 resistant hormone refractory 70 TAXOTERE R 70 VFEND 70 paclitaxel Taxol R 70 erythropoietic 70 refractory colorectal cancer 70 Thal Dex 70 acetonide FA 70 refractory gout 70 hyperplasia BPH 70 novel VDA molecule 70 Oral Fingolimod 70 myeloid metaplasia 70 corticosteroid therapy 70 GAMMAGARD 70 Degarelix 70 Xelox 70 rituximab Rituxan 70 biochemical relapse 70 preoperative chemotherapy 70 Relapsing Remitting Multiple Sclerosis 70 canakinumab 70 pediatric acute lymphoblastic 70 bortezomib Velcade R 70 mild renal insufficiency 70 bone marrow reticulin deposition 70 Relapsed Refractory 70 TO AVOID PREGNANCY WHILE 70 esophageal gastric 70 adjuvant radiotherapy 70 pegylated interferon alfa 2b 70 Leukemias 70 cinacalcet 70 vWD 70 MYLOTARG 70 Relapsed Refractory Multiple Myeloma 70 toenail onychomycosis 70 VELCADE melphalan 70 Teriflunomide 70 STRIDE PD 70 #mg BID [001] 70 grade cervical intraepithelial 70 thrombocytopenic 70 Amrubicin 70 Blinatumomab 70 receiving highly emetogenic 70 brivaracetam 70 Castration Resistant Prostate Cancer 69 pulmonary metastasis 69 malignant lymphomas 69 Anti VEGF 69 anagrelide 69 stage IIIb 69 denileukin diftitox 69 Gleevec imatinib 69 CLARITY study 69 lymphoid malignancies 69 Folfox 69 dual endothelin receptor antagonist 69 pancreatic carcinoma 69 refractory metastatic 69 Dementia Related Psychosis 69 refractory CLL 69 dasatinib Sprycel 69 Cimzia TM 69 refractory AML 69 Aptivus ® 69 primary immunodeficiency PI 69 peritoneal cancer 69 leukemia ALL 69 mycophenolate mofetil 69 TTR amyloidosis 69 refractory indolent non 69 advanced hepatocellular carcinoma 69 OMP #R# 69 decompensated liver disease 69 null responder 69 neovascular diseases 69 mertansine 69 AVASTIN 69 PEGINTRON TM 69 pamidronate 69 interferon gamma 1b 69 metastatic renal 69 Romiplostim 69 catheter occlusion 69 adenomatous 69 MALT lymphoma 69 resectable 69 colorectal adenoma 69 locoregional recurrence 69 lymphocytosis 69 CIMZIA ™ 69 Adjunctive 69 docetaxel Taxotere R 69 oropharyngeal candidiasis OPC 69 Myelofibrosis 69 antiangiogenic agent 69 treat benign prostatic 69 Idiopathic Pulmonary Fibrosis IPF 69 INSPIRE Trial Phase III 69 mapatumumab 69 EGFR tyrosine kinase inhibitors 69 teriflunomide 69 antimetabolite 69 BRAF V#E mutation 69 achieved ACR# 69 oral ridaforolimus 69 liposomal doxorubicin 69 Virulizin ® 69 Known hypersensitivity 69 cutaneous melanoma 69 pediatric malignancies 69 neutropenia dehydration dyspnea 69 Acute myeloid leukemia 69 headache nasopharyngitis 69 8mg/kg 69 Arranon 69 pulmonary hypertension PH 69 benign prostatic hypertrophy BPH 69 adjuvant cisplatin 69 ribavirin therapy 69 Severe Sepsis 69 mutated K ras 69 CTAP# Capsules 69 CP CPPS 69 Fibrillex TM 69 bortezomib Velcade 69 Glioblastoma multiforme GBM 69 subependymal giant cell 69 hormone refractory metastatic prostate 69 Golimumab 69 mutated KRAS 69 DFMO 69 Pegylated Interferon 69 TNF Tumor Necrosis Factor 69 prostate cancer PCa 69 mildly symptomatic 69 autoantibody positive 69 chemoradiotherapy 69 biologic DMARD 69 verteporfin 69 chronic myeloid 69 squamous cell lung cancer 69 pouchitis 69 stage IIIA 69 Fludara ® 69 chronic myocardial ischemia 69 β blockers 69 chronic idiopathic thrombocytopenic purpura 69 doxorubicin cyclophosphamide 69 Nebulized 69 palifermin 69 unfractionated heparin UFH 69 Sapacitabine 69 Alemtuzumab 69 hematopoietic cancers 69 aldosterone antagonists 69 gastrointestinal stromal tumor 69 oral mTOR inhibitor 69 nonalcoholic steatohepatitis NASH 69 aspirin clopidogrel 69 PNP inhibitor 69 imatinib Gleevec 69 Zevalin R Ibritumomab 69 argatroban 69 dose escalation clinical 69 HNSCC 69 nephrotoxicity 69 Pyridorin 69 T1c 69 Omacetaxine 69 urothelial cancer 69 Papillary 69 CHAMPION PCI 69 prostate carcinoma 69 cyclophosphamide methotrexate 69 Romidepsin 69 non squamous NSCLC 69 mycophenolate mofetil MMF 69 virus HCV protease inhibitor 69 splenectomized 69 multicenter Phase II 69 unresectable locally advanced 69 acute myeloid 69 precancerous condition 69 PD LID 69 HER2 positive cancers 69 bendamustine 69 PAOD 69 myocardial infarction ventricular fibrillation 69 oral rivaroxaban 69 Philadelphia Chromosome Positive 69 epithelial tumors 69 salmeterol fluticasone 69 dacarbazine DTIC 69 vidofludimus 69 immunocompetent 69 Phase #b/#a clinical 69 weekly subcutaneous injections 69 non resectable 69 DEB# 69 cytoreduction 69 acute humoral rejection 69 steroid refractory 69 HMG CoA reductase inhibitors 69 basal cell carcinoma BCC 69 PSMA ADC 69 ADPKD 69 transplantation HSCT 69 immune thrombocytopenic purpura ITP 69 HeFH 69 cis retinoic acid 69 metastatic androgen independent 69 docetaxel chemotherapy 69 Azacitidine 69 sunitinib Sutent 69 hematological malignancy 69 constipation OIC 69 bronchogenic carcinoma 69 chemoresistant 69 multiple myeloma MM 69 tipranavir ritonavir 69 receiving INTRON 69 Deforolimus 69 Dasatinib 69 fistulizing Crohn disease 69 CsA 69 Intravenous immunoglobulin 69 mycophenolic acid 69 anthracycline containing 69 intravenous cyclophosphamide 69 superficial basal cell carcinoma 69 Renal Impairment 69 5 Fluorouracil 69 peritoneal carcinomatosis 69 diarrhea predominant irritable 69 alemtuzumab treated 69 Aplidin 69 intravesical infusion therapy 68 platelet inhibitor 68 hemorrhagic cystitis 68 hypervascular tumors 68 relapsed ALL 68 ULORIC 68 Soft Tissue Sarcoma 68 non resectable metastatic 68 ancrod 68 adefovir dipivoxil 68 clodronate 68 recombinant tissue plasminogen 68 microtubule inhibitor 68 Navelbine ® 68 aflibercept VEGF Trap 68 nilotinib Tasigna ® 68 SSc 68 adult chronic ITP 68 histologically proven 68 mg kg dose 68 AGILECT R 68 sitaxsentan 68 noninvasive outpatient 68 HBeAg + 68 IL# PE#QQR 68 factor TNF 68 systemic RNAi therapeutic 68 GSK# [001] 68 opioid naive 68 rituximab refractory 68 Diffuse Large B 68 combination antiretroviral therapy 68 tenofovir emtricitabine 68 occlusive disease 68 Vincristine 68 nonsmall cell lung cancer 68 Neoadjuvant 68 BCG refractory carcinoma 68 chronic granulomatous disease 68 Elotuzumab 68 neoadjuvant treatment 68 Fingolimod 68 Noxafil 68 Diabetic Macular Edema DME 68 GnRH agonists 68 lumiliximab 68 colorectal adenocarcinoma 68 Pulmonary Arterial Hypertension PAH 68 heparin induced thrombocytopenia 68 gastrointestinal stromal tumors 68 bleomycin 68 pan HDAC inhibitor 68 vandetanib 68 Follicular Lymphoma 68 pain palliation 68 Kit CD# positive 68 Tyrima 68 phase IIb trial 68 VNP#M 68 proliferative retinopathy 68 curative resection 68 pyridostigmine 68 huC# DM4 68 ritonavir boosted lopinavir 68 neoadjuvant chemotherapy 68 pomalidomide 68 Refractory Hodgkin Lymphoma 68 NMDA antagonist 68 refractory ovarian cancer 68 ELOXATIN 68 docetaxel prednisone 68 Epratuzumab 68 IFN beta 68 Patients Receiving 68 follicular lymphomas 68 intravenous tissue plasminogen 68 ertapenem 68 Ischemic 68 Hydroxyurea 68 Pegloticase 68 NovoTTF 68 idarubicin 68 ANCA associated 68 induce orthostatic hypotension 68 pegylated interferon alpha 68 Hedgehog Pathway Inhibitor 68 metastatic lymph nodes 68 Traficet EN 68 BR.# 68 RRMS patients 68 Phase 2b Clinical Trial 68 acute leukemias 68 Randomized Phase II 68 clevidipine 68 nadolol 68 mcg BID 68 T#I [002] 68 allogeneic bone marrow 68 R lenalidomide 68 HBeAg positive 68 neurological manifestations 68 Systemic Sclerosis 68 TNF antagonist 68 vapreotide acetate 68 ibandronate 68 Endometrial 68 BCIRG 68 blinded randomized placebo controlled 68 transthyretin amyloidosis 68 clomipramine 68 Safinamide 68 receiving VELCADE 68 HGS ETR2 68 hypercholesterolemic patients 68 Subgroup analysis 68 Adjuvant therapy 68 plus dexamethasone 68 primary hyperparathyroidism 68 prostate cancer mCRPC 68 invasive lobular carcinoma 68 inhibitor RG# 68 neurologic progression 68 BoNTA 68 hepatitis C genotype 68 tyrosine kinase inhibitors TKIs 68 perioperatively 68 lexidronam injection 68 Relapsing remitting MS 68 Phase IIIb clinical 68 myeloproliferative diseases 68 C1 INH deficiency 68 PKC# 68 bladder carcinoma 68 edifoligide 68 CTAP# 68 chemotherapy cisplatin 68 ALA PDT 68 papillary carcinoma 68 bladder ovarian 68 midstage clinical 68 nevirapine Viramune 68 HBeAg 68 TLK# 68 hepatitis C HCV 68 5-fluorouracil/leucovorin 68 CIPN 68 BCG refractory 68 alpha1 antitrypsin deficiency 68 Hormone Refractory Prostate Cancer 68 rufinamide 68 histone deacetylase HDAC inhibitor 68 flutamide 68 Chronic Lymphocytic Leukemia CLL 68 PLX STROKE targeting 68 LymphoStat B belimumab 68 Seliciclib 68 Amgen Neulasta R 68 intravesical therapy 68 Pivotal Phase III 68 liposomal amphotericin B 68 investigational monoclonal antibody 68 HER2 expression 68 #mg ATC 68 flavopiridol 68 posaconazole 68 Hematologic 68 acute lymphoblastic 68 Acute Myelogenous Leukemia AML 68 viral kinetics 68 hematologic toxicity 68 Telintra 68 Mg Usa 68 retinal vein occlusion induced 68 thoracoscopic lobectomy 68 Virologic 68 Investigational Treatment 68 concurrent chemoradiation 68 non nucleoside inhibitor 68 doxorubicin Adriamycin 68 panitumumab Vectibix 68 Hepatotoxicity 68 refractory anaplastic astrocytoma 68 receiving XGEVA 68 dopamine receptor agonist 68 EGFR mutation positive 68 metastatic castrate resistant 68 mCRC patients 68 PEGylated anti 68 symptomatic BPH 68 AA amyloidosis 68 PROSTVAC VF 68 ATACAND 68 SCIg 68 asymptomatic metastatic 68 bullous 68 Bayer HealthCare Onyx Pharmaceuticals 68 weekly intravenous infusions 68 Squamous 68 2 methoxyestradiol 68 gemcitabine Gemzar 68 hepatocellular carcinoma HCC 68 Tolvaptan 68 patients coinfected 68 Dacogen decitabine 68 neuroendocrine cancers 68 Irinotecan 68 vaso occlusive crisis 68 anthracycline chemotherapy 68 de novo AML 68 severe exacerbations 68 Complicated Skin 68 BRAF inhibitor 68 Peginterferon 68 Platinol ® cisplatin 68 APTIVUS ritonavir 68 Femara letrozole 68 SYN# 68 tarenflurbil 68 gamma secretase inhibitor 68 telaprevir dosed 68 ximelagatran 68 Trastuzumab 68 Inhaled nitric oxide 68 indinavir Crixivan 68 Rilonacept 68 Malignant Glioma 68 metastatic kidney 68 anti angiogenic agents 68 Patients Treated With 68 IMA# 68 unstable angina pectoris 68 p# biomarker 68 TNF blocker therapy 68 docetaxel Taxotere 68 Chronic Myeloid Leukemia 68 relapsed Acute Myeloid 68 Atypical Hemolytic Uremic Syndrome 68 trans retinoic acid 68 Vidaza ® 68 Acute Coronary Syndromes ACS 68 Squalamine 68 efalizumab 68 metastatic uveal melanoma 68 pretransplant 68 Acute Myelogenous Leukemia 68 mg/m2 dose 68 pericardial effusion 68 atypical hemolytic uremic syndrome 68 5-FU/LV 68 NSABP B 68 Anthracycline 68 pediatric Crohn disease 68 visilizumab 68 saline placebo 68 histone deacetylase inhibitor 68 lymphoma CTCL 68 oxaliplatin Eloxatin 68 debulking surgery 68 hypertrichosis occurred 68 HIV coinfected 68 dexamethasone Decadron 68 refractory chronic myeloid 68 pT2 68 INTEGRILIN R 68 advanced carcinoid 68 Eculizumab 68 Abrupt discontinuation 68 Forodesine HCl 68 ThermoDox R 68 induced macular edema 68 ankylosing spondylitis AS 68 PhG alpha 1 68 gemcitabine cisplatin 68 melphalan prednisone 68 Temodar ® 68 underwent liver transplantation 68 Chronic Hepatitis C 68 moderate hepatic impairment 68 CINTREDEKIN BESUDOTOX 68 idraparinux 68 crizotinib PF # 68 Proellex TM 68 Proxinium TM 68 Albuferon TM 68 acute mania 68 Mg Uk 68 Annamycin 67 FOLFIRI alone 67 liposomal formulation 67 reduce serum phosphate 67 fluoropyrimidine 67 either acutely decompensated 67 renoprotective 67 PEG IFN 67 APPRAISE 67 Advanced Melanoma 67 pancreatic islet cell 67 primary hypercholesterolemia 67 arthritis PsA 67 Xanafide 67 endocrine therapies 67 pulmonary metastases 67 zoledronate 67 choroidal vasculopathy 67 IV metastatic melanoma 67 paclitaxel Taxol ® 67 beta 1a 67 humanized interleukin 6 67 Motesanib 67 Daclizumab 67 dopaminergic therapy 67 AEG# 67 HCV NS5B polymerase 67 cabazitaxel 67 targeted radiotherapeutic 67 Advaxis Phase 67 Polyneuropathy 67 neutropenic patients 67 CBLC# 67 androgen deprivation 67 mutated KRAS gene 67 atrioventricular block 67 hyperacute 67 DOXIL 67 Stage IIB 67 cardiotoxic 67 prostate cancer HRPC 67 randomized multicenter trial 67 infliximab Remicade 67 secondary hyperparathyroidism 67 Multiple Myeloma MM 67 leukemia APL 67 AVONEX ® 67 ALT normalization 67 Bronchiectasis 67 treatment naïve genotype 67 HBeAg seroconversion 67 liver transplant recipients 67 bevacizumab Avastin R 67 parecoxib 67 achieved sustained virologic 67 localized renal 67 gastrointestinal stromal tumors GISTs 67 unresectable HCC 67 relapsing remitting multiple sclerosis 67 Gamunex C 67 chemosensitizer 67 orally administered inhibitor 67 carcinoid tumors 67 Vitaxin 67 PegIFN RBV 67 lung metastasis 67 Chronic Myelogenous Leukemia CML 67 CYP#A# substrate 67 immune modulator 67 included exfoliative dermatitis 67 malignant pleural mesothelioma MPM 67 pemphigus vulgaris 67 refractory cutaneous T 67 Quinamed 67 velafermin 67 budesonide foam 67 refractory prostate cancer 67 cranial irradiation 67 Antitumor Activity 67 Acute Myeloid Leukaemia AML 67 relapsing MS 67 Tavocept 67 ExTRACT TIMI 67 RoACTEMRA 67 evaluating Prochymal 67 Akt inhibitor 67 AZT zidovudine Retrovir 67 phase III isavuconazole 67 FOLFOX4 67 Kinoid 67 bleeding pallor 67 undergoing peritoneal dialysis 67 lupus nephritis 67 diabetic kidney 67 liver resection 67 Radical prostatectomy 67 nonmetastatic prostate cancer 67 Gemzar gemcitabine 67 EURIDIS 67 antiarrhythmic drug 67 antithrombotic therapy 67 tigecycline 67 anastrazole 67 doxorubicin docetaxel 67 Relapsing Multiple Sclerosis 67 endothelin receptor antagonists 67 Acute Bacterial Sinusitis ABS 67 tanespimycin 67 R Saizen R 67 EOquin TM phase 67 paraganglioma 67 murine model 67 Metastatic Melanoma 67 micafungin 67 acute promyelocytic leukemia 67 iniparib BSI 67 moderate renal impairment 67 daily subcutaneous injections 67 tumor histology 67 5 FU leucovorin 67 intravenous iv 67 overt nephropathy 67 venlafaxine XR 67 nondiabetic patients 67 AVOREN 67 BRIM3 67 3TC lamivudine Epivir 67 pCR 67 taxane therapy 67 IMPACT DCM 67 follicular lymphoma FL 67 Sudhir Agrawal D.Phil 67 potent antiproliferative 67 fluvastatin 67 RhuDex R 67 HuMax EGFr 67 vinorelbine tartrate 67 Meets Primary Endpoint 67 Methylnaltrexone 67 Bosentan 67 Advanced Renal Cell 67 nucleotide analog 67 oral FTY# 67 boosted protease inhibitor 67 TMP SMX 67 acute myelogenous leukemia AML 67 elotuzumab 67 Malignant Melanoma 67 olmesartan